(LUNG) Pulmonx - Overview
Stock: Zephyr Valve, Chartis System, LungTraX Platform
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 104% |
| Relative Tail Risk | -12.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.94 |
| Alpha | -90.46 |
| Character TTM | |
|---|---|
| Beta | 0.931 |
| Beta Downside | 0.935 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.06% |
| CAGR/Max DD | -0.49 |
Description: LUNG Pulmonx January 14, 2026
Pulmonx Corporation (NASDAQ:LUNG) is a commercial-stage medical-technology firm that commercializes a minimally invasive bronchoscopic solution for patients with severe emphysema, a subset of chronic obstructive pulmonary disease (COPD). Its product suite includes the Zephyr Endobronchial Valve for lung-volume reduction, the Chartis Pulmonary Assessment System (a balloon catheter with flow- and pressure-sensing console to evaluate collateral ventilation), and the cloud-based LungTraX Platform, which offers quantitative CT analytics such as LungTraX Connect, LungTraX Detect, and the StratX Lung report to identify target lobes for valve therapy.
As of the most recent FY 2023 filing (assumed to be the latest audited 10-K), Pulmonx reported revenue of roughly $84 million, a cash balance near $200 million, and a net loss of $30 million, reflecting ongoing investment in R&D and market expansion. The company operates in the United States, Europe, the Middle East, Africa, and the Asia-Pacific, leveraging a growing COPD patient base-estimated at >16 million adults in the U.S. alone, with prevalence expected to rise as the population ages. Reimbursement dynamics are a key economic driver: Medicare’s coverage of bronchoscopic lung-volume reduction (BLVR) procedures has broadened in recent years, improving payer acceptance and potentially accelerating adoption of Zephyr valves.
Sector-wide, the health-care equipment sub-industry is being shaped by an aging demographic, increasing demand for minimally invasive therapies, and competitive pressure from alternative BLVR technologies (e.g., endobronchial coils and thermal vapor ablation). Investors should monitor Pulmonx’s pipeline milestones, real-world outcomes data, and the trajectory of Medicare reimbursement rates, as these factors materially affect cash flow sustainability. For a deeper quantitative assessment of LUNG’s valuation metrics, see the ValueRay analysis.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -56.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA -2.81 > 1.0 |
| NWC/Revenue: 96.39% < 20% (prev 154.6%; Δ -58.24% < -1%) |
| CFO/TA -0.23 > 3% & CFO -32.1m > Net Income -56.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.9m) vs 12m ago 4.23% < -2% |
| Gross Margin: 73.30% > 18% (prev 0.74%; Δ 7256 % > 0.5%) |
| Asset Turnover: 59.97% > 50% (prev 47.37%; Δ 12.60% > 0%) |
| Interest Coverage Ratio: -17.27 > 6 (EBITDA TTM -54.4m / Interest Expense TTM 3.23m) |
Altman Z'' -15.00
| A: 0.64 (Total Current Assets 111.2m - Total Current Liabilities 22.9m) / Total Assets 138.3m |
| B: -3.70 (Retained Earnings -511.1m / Total Assets 138.3m) |
| C: -0.36 (EBIT TTM -55.7m / Avg Total Assets 152.8m) |
| D: -6.50 (Book Value of Equity -508.9m / Total Liabilities 78.2m) |
| Altman-Z'' Score: -17.14 = D |
Beneish M -2.82
| DSRI: 1.00 (Receivables 14.3m/12.3m, Revenue 91.7m/79.3m) |
| GMI: 1.01 (GM 73.30% / 73.91%) |
| AQI: 1.46 (AQ_t 0.05 / AQ_t-1 0.03) |
| SGI: 1.16 (Revenue 91.7m / 79.3m) |
| TATA: -0.18 (NI -56.8m - CFO -32.1m) / TA 138.3m) |
| Beneish M-Score: -2.82 (Cap -4..+1) = A |
What is the price of LUNG shares?
Over the past week, the price has changed by -8.54%, over one month by -35.62%, over three months by -17.13% and over the past year by -76.67%.
Is LUNG a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LUNG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.8 | 283.3% |
| Analysts Target Price | 5.8 | 283.3% |
| ValueRay Target Price | 0.8 | -45.3% |
LUNG Fundamental Data Overview February 03, 2026
P/S = 0.738
P/B = 1.1818
Revenue TTM = 91.7m USD
EBIT TTM = -55.7m USD
EBITDA TTM = -54.4m USD
Long Term Debt = 37.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.24m USD (from shortTermDebt, last quarter)
Debt = 56.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -20.0m USD (from netDebt column, last quarter)
Enterprise Value = 47.7m USD (67.6m + Debt 56.6m - CCE 76.5m)
Interest Coverage Ratio = -17.27 (Ebit TTM -55.7m / Interest Expense TTM 3.23m)
EV/FCF = -1.46x (Enterprise Value 47.7m / FCF TTM -32.6m)
FCF Yield = -68.44% (FCF TTM -32.6m / Enterprise Value 47.7m)
FCF Margin = -35.59% (FCF TTM -32.6m / Revenue TTM 91.7m)
Net Margin = -61.91% (Net Income TTM -56.8m / Revenue TTM 91.7m)
Gross Margin = 73.30% ((Revenue TTM 91.7m - Cost of Revenue TTM 24.5m) / Revenue TTM)
Gross Margin QoQ = 74.65% (prev 72.11%)
Tobins Q-Ratio = 0.34 (Enterprise Value 47.7m / Total Assets 138.3m)
Interest Expense / Debt = 1.42% (Interest Expense 805.0k / Debt 56.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -44.0m (EBIT -55.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.86 (Total Current Assets 111.2m / Total Current Liabilities 22.9m)
Debt / Equity = 0.94 (Debt 56.6m / totalStockholderEquity, last quarter 60.0m)
Debt / EBITDA = 0.37 (negative EBITDA) (Net Debt -20.0m / EBITDA -54.4m)
Debt / FCF = 0.61 (negative FCF - burning cash) (Net Debt -20.0m / FCF TTM -32.6m)
Total Stockholder Equity = 73.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.13% (Net Income -56.8m / Total Assets 138.3m)
RoE = -77.58% (Net Income TTM -56.8m / Total Stockholder Equity 73.1m)
RoCE = -50.59% (EBIT -55.7m / Capital Employed (Equity 73.1m + L.T.Debt 37.0m))
RoIC = -39.92% (negative operating profit) (NOPAT -44.0m / Invested Capital 110.3m)
WACC = 5.60% (E(67.6m)/V(124.2m) * Re(9.35%) + D(56.6m)/V(124.2m) * Rd(1.42%) * (1-Tc(0.21)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.28%
Fair Price DCF = unknown (Cash Flow -32.6m)
EPS Correlation: 59.43 | EPS CAGR: 96.62% | SUE: 4.0 | # QB: 2
Revenue Correlation: 93.28 | Revenue CAGR: 12.75% | SUE: 1.12 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.34 | Chg30d=+0.000 | Revisions Net=+3 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.34 | Chg30d=+0.000 | Revisions Net=+3 | Growth EPS=+8.7% | Growth Revenue=+5.1%